Successful use of ketamine for intractable cancer pain
- 388 Downloads
Goals and work
Despite medical awareness, intractable pain is a serious problem in cancer and occurs in up to 2% of advanced cancer patients. However, few data are available concerning the optimal treatment of such patients. The emergence of intractable pain may notably be due to the activation of N-methyl-D-aspartate (NMDA) receptors located in the central nervous system. NMDA antagonists might thus be an interesting approach in such pain syndromes.
Patients and methods
Twelve patients with intractable cancer pain received a test dose of 5–10 mg of ketamine, a strong NMDA antagonist, in order to determine their response and tolerance to the drug. Continuous intravenous infusions of ketamine associated with morphine were then administered.
The acute test dose was successful in all cases (VAS <3/10 after 5 min). The prolonged use of ketamine allowed us to reduce the total daily dose of morphine required (range: 200–1,200 mg) by 50% and allowed eight patients to go home with a portable pump with morphine and ketamine during a relatively long period of time (range: 7–350 days, median: 58 days). Side effects were moderate (dizziness) and they were limited to the test phase.
Our data suggest the importance of NMDA receptors in the genesis of chronic cancer pain and indicate that NMDA antagonists should be further studied for the management of cancer pain and, in particular, intractable pain.
KeywordsCancer pain Intractable pain Morphine Ketamine
- 3.Byas-Smith MG, Max MB, Gracely RH, Bennet GJ (1993) Intravenous ketamine and alfentanil in patients with chronic causalgic pain and allodynia (abstract). 7th World Congress on Pain 454–455Google Scholar
- 5.Dickenson AH (1997) NMDA receptor antagonists: interactions with opioids. Acta Anesthesiol Scand 41:112–115Google Scholar
- 8.Klepstadt P, Maurset A, Moberg ER, Oye I (1990) Evidence of a role of NMDA receptors in pain perception. Eur. J. Pharmacol 187:513–518Google Scholar
- 9.Lossignol DA (1993) Pitfalls in the use of opiates in treatment of cancer pain. Support. Care Cancer 1:256–258Google Scholar
- 10.Lossignol DA, Bredas P and Obiols M (1995) Patient controlled analgesia in cancer patients (abstract). Support. Care Cancer 3:356Google Scholar
- 11.Lossignol DA (1989) Ketamine and morphine in cancer pain: preliminary report. Topics on Supportive Care in Cancer 6–9Google Scholar
- 18.Sosnowsky M, Lossignol DA, Fodderie L (1993) Reversibility of opioid insensitive pain (abstract). 7th World Congress on Pain 16Google Scholar
- 19.Wagemans MFM, Bakker EN, Zuurmond WWA, Spoelder EN, Loenen AC, De Lange JJ (1995) Intrathecal administration of high-dose morphine solutions decreases the pH of cerebrospinal fluid, Pain 61:55–59Google Scholar